Design of HIV-1 Protease inhibitors
Molecular Docking Studies; Dietary Compounds As HIV 1 Protease Inhibitors
... Originally, structure-based drug design was equated with De novo design or building a molecule from ground up [16]. The active site of the protein was a space to be filled with a molecule that complemented ...
16
QSAR MODELING FOR INHIBITORY ACTIVITY OF NON PEPTIDE HIV 1 PROTEASE INHIBITORS: A MLR APPROACH
... the design of a QSAR study presents two main advantages: (a) the compounds and their various fragments and substituent’s can be directly characterized on the basis of their molecular structure only; and (b) the ...
13
Exploring QSARs for Inhibitory Activity of Non-peptide HIV-1 Protease Inhibitors by GA-PLS and GA-SVM
... Owing to its remarkable generalization performance, the SVM has attracted attention and gained extensive application, such as pattern recognition problems (17,19), drug design (20), QSAR (21,22), and quantitative ...
9
Design and synthesis of inhibitors for the HIV 1 protease
... moderate inhibitors (pM) of the HIV-1 ...hydroxyethylamine inhibitors were not followed by the phosphonamidate methyl ...hydroxyl-containing inhibitors Is more easily achieved as these ...
161
Protease mediated maturation of HIV: Inhibitors of protease and the maturation process
... drug design unfeasible at the current ...maturation inhibitors has highlighted a need to further our understanding of the CA-SP1 region of Gag and its role in HIV-1 particle ...inhibit ...
14
HIV protease inhibitors: a review of molecular selectivity and toxicity
... Designing inhibitors based on the substrate envelope of HIV protease is a recent strategy for developing HIV protease ...substrate-based HIV protease inhibitor, RO1, has ...
10
Safety of protease inhibitors in HIV-infected pregnant women
... specific methodology for systematic reviews or meta-analyses. The increasing exposure to antiretroviral therapy, including HAART, in resource-poor countries, calls for a thorough assessment. In these settings, large ...
10
Multidimensional QSAR Modeling of Amprenavir Derivatives as HIV Protease Inhibitors
... On comparing the models generated by Topomer CoMFA, Quasar and Raptor we can see similarity in r 2 and q 2 values. Thus, we can conclude that the models generated by these two technologies are similar to each other even ...
16
A combined 3D-QSAR and docking studies for the In-silicoprediction of HIV-protease inhibitors
... Conclusion: The combination of two computational techniques would helped to make a clear decision that compound 32 with well inhibitory activity bind more efficiently within the binding pocket even in case of mutant ...
12
Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV 1 infected children
... (data not shown) but it was not identify as a prognostic factor due to the short period of follow-up included in our study. In the multivariate analyses only the number of drugs used according with the CCO2 and a lower ...
5
Selection of Drug-Resistant Feline Immunodeficiency Virus (FIV) Encoding FIV/HIV Chimeric Protease in the Presence of HIV-Specific Protease Inhibitors
... the design of drugs against HIV-1 ...geting HIV-1 PR in infected patients, and multidrug therapy com- bining them with drugs against other targets, primarily RT, has greatly improved ...
11
QSAR Modeling Of Anti HIV Protease Inhibitors Using Quantum Chemical Descriptors
... CONCLUSIONS The QSAR studies based on different chemical descriptors for these 30 models i.e., PA1 to PA30, reveals that best QSAR model i.e. PA30, is obtained by the MLR analysis by taking molecular weight, total energy ...
6
Reviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance: Insights for Possible Novel Gag Inhibitor Designs
... ABSTRACT HIV protease inhibitors against the viral protease are often hampered by drug resistant mutations that are found in protease and in the viral substrate ...alongside ...
23
Novel macromolecular inhibitors of human immunodeficiency virus-1 protease
... in vivo selection to the wild-type revertant form during a gene therapy application. Here, we present a new strategy for the design of macro- molecular inhibitors of HIV-1 PR. The hydrophobic ...
9
An in-silico investigation of Morita-Baylis-Hillman accessible heterocyclic analogues for applications as novel HIV-1 C protease inhibitors
... subtype HIV-1 viral strains, they display subtle differences in the drug responses and development of resistance in their proteases (Ahmed et ...ligand design with improved specificity coupled with ...
104
The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors
... and protease enzymes, the molecular targets of antiretroviral ...that HIV-1 RT and protease susceptibility testing be used to help select antiretroviral drugs for HIV-1-infected ...
18
Design and synthesis of HIV-1 integrase inhibitors
... years HIV-1 has also become increasingly prevalent within African American and Hispanic/Latino communities in many Southern states as well as certain urban areas in the North-east and ...state. ...
439
QSAR Study and Determination of More Potent Peptidic HIV-1- Protease Inhibitors
... Department of Chemistry, Shia P.G. College, Lucknow, U.P., INDIA Abstract QSAR study of three sets of peptidic HIV-protease inhibitors has been studied. The descriptor used for study is log P. For ...
10
The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?
... Wiesmann 1* , Jan Vachta 1 , Robert Ehret 1 , Hauke Walter 2 , Rolf Kaiser 3 , Martin Stürmer 4 , André Tappe 5 , Martin Däumer 6 , Thomas Berg 7 , Gudrun Naeth 1 , Patrick Braun 1 , ...
9
Studies directed towards the synthesis of chromone carbaldehyde-derived HIV-1 protease inhibitors
... Schematic representation of hydrogen-bonding interactions between compound 263 (conformer 1) and the HIV -1 protease receptor cavity in the presence of a s tructural water molecul[r] ...
288